# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Longeveron shares surged after FDA granted RMAT designation to Lomecel-B for mild Alzheimer's Disease. This designation, th...
VVPR: 119% | VivoPower Secures Amendment And Extension To $34M Shareholder Loan Financing Agreement Following Negotiations With...
Lomecel-B is a proprietary, scalable, allogeneic cellular investigational therapy being evaluated across multiple indications, ...